Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors

Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) represent a major breakthrough in cancer therapy. Immune-related adverse events (irAEs) may occur during treatment due to their unique mechanism of action. Dermatologic toxicities appear to be one of the most prevalent irAEs. The most common symptoms are maculopap...

Full description

Bibliographic Details
Main Authors: Xiaoyan SI, Chunxia HE, Li ZHANG, Xiaowei LIU, Yue LI, Hanping WANG, Xiaoxiao GUO, Jiaxin ZHOU, Lian DUAN
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2019-10-01
Series:Chinese Journal of Lung Cancer
Subjects:
Immune checkpoint inhibitor
Immunotherapy-related toxicities
Dermatologic toxicities
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2019.10.06

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2019.10.06

Similar Items